PARP1 and hematopoietic and lymphoid system neoplasm: Although the majority of the clinical data are in the space of epithelial cancer, PARP inhibitors and other DDR inhibitors targeting ATM, ATR, CHK1/2, WEE1 and DNA-PK are being studied in a variety of hematologic neoplasms (7, 8).